PHILADEPHIA, PA - Whether you barbecue on a top-of-the-line multi-burner grill or a less expensive model, some things never change. Spark-ups, spills, grease-fires, and flare-ups are going to happen when cooking in the backyard.
PHILADEPHIA, PA - Whether you barbecue on a top-of-the-line multi-burner grill or a less expensive model, some things never change. Spark-ups, spills, grease-fires, and flare-ups are going to happen when cooking in the backyard.
Arlington, VA – Always enhancing the platform to support operators’ evolving needs, restaurant commerce platform GoTab has just unveiled enhanced contactless menu features.
Philadelphia, PA - In the wake of the first COVID wave, NextFab launched an 8-week accelerator program for its entrepreneurially-minded members. The accelerator aims to provide artisans with the essential tools, support, and structure they need to build viable businesses.
Arlington, VA – As hospitality operators across the country consider new ways to operate or look to launch new concepts in 2021, restaurant commerce platform GoTab unveils a new Contactless Ordering Starter Kit designed to equip them with all the hardware and software needed to run contactless dine-in, takeout, and delivery operations.
Arlington, VA – As winter weather, local restrictions, and shutdowns start challenging hospitality operations across the country, restaurant commerce platform GoTab is helping operators pivot and seamlessly transform their business operations, from adding catering services for the holiday season to transforming restaurants into retail markets and grocery stores. GoTab’s unique features and key integrations also allow operators to run profitable operations and easily pivot between dine-in service, takeout, curbside pickup and delivery, catering, and retail market services.
CAMBRIDGE, Mass.- Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.